Pharma Business - September 17, 2026
Independent study broadens use case for Lumito’s SCIZYS platform
A newly published, peer-reviewed study has used Lumito's SCIZYS tissue-imaging platform to analyse biomarker expression in single immune cells, extending its validated use beyond tissue samples into cell-based research for the first time.
Pharma Diagnostics - September 14, 2026
Study finds Acarix’s CADScor platform can also detect heart failure
A peer-reviewed study led by Aalborg University has found that the seismocardiography technology behind Acarix's CADScor System can detect heart failure with diagnostic accuracy comparable to a standard blood test, and with substantially fewer false positives – a condition distinct from the coronary artery disease the device is currently cleared for.
Agreement - July 14, 2026
Prolight signs development agreement with BRAINBox
Prolight Diagnostics has announces the successful completion of a 260-patient feasibility study and the subsequent signing of a development agreement with BRAINBox Solutions.
Collaboration - May 19, 2025
Elypta is main partner in European hereditary multi-cancer screening project
Elypta has announced its role as a main partner in PREDI-LYNCH, a European initiative aimed at transforming early cancer detection for individuals with Lynch Syndrome (LS).
Drug Development Pharma - March 24, 2025
New findings about Elypta’s urine test in kidney cancer follow-up
Elypta has announced that findings from the international AURORAX-0087A (AUR87A) study, the largest diagnostics study ever conducted on the most common type of kidney cancer, were presented today in a Plenary Game Changer Session at the 2025 European Association of Urology Congress.
Business article - March 12, 2025
Boule Diagnostics closes BM950 project and announces new portfolio strategy
Boule Diagnostics announces the decision to close the BM950 project due to newly identified technical issues that have significantly impacted the project’s time to market and overall profitability.
